Simulations Plus (SLP) Akcija Kursas
Simulations Plus Kursas
Per pastaruosius 19 metus Simulations Plus pajamos augo 14,7 % kasmet ir pasiekė 79,18 mln. USD. Pelnas akcijai augo 15,0 % per metus per pastaruosius 18 metus. Simulations Plus grynoji marža −81,7 % yra sumažėjo palyginti su 21,1 % prieš kelerius metus. Esama kaina dividendo pajamingumas yra apie 0,97 %. Išmokų koeficientas yra apie 37 % pelno. Simulations Plus 12 mėn. konsensuso tikslinė kaina yra 18,50 USD, apie virš kursą 0,0 %. Iš 12 analitikų 0 rekomenduoja pirkti — bendras konsensusas yra Parduoti.
Simulations Plus akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
Simulations Plus akcija ir akcijų analizė
Dažnai užduodami klausimai apie Simulations Plus akciją
Simulations Plus Inc is primarily active in the pharmaceutical and biotechnology industries. With a focus on simulation software and consulting services, the company provides cutting-edge solutions for drug discovery and development. Simulations Plus Inc's expertise in modeling and simulation technologies helps pharmaceutical companies optimize their drug formulation and dosage strategies. By leveraging their industry-leading software platforms, Simulations Plus Inc supports the efficient research and development of new therapies, enhancing the overall success and effectiveness of pharmaceutical companies.
The main competitors of Simulations Plus Inc in the market include Certara, Inc and Dassault Systèmes.
The business model of Simulations Plus Inc revolves around providing software and consulting services for pharmaceutical research and development. As a leading provider in the field of drug discovery and development, Simulations Plus Inc aims to enhance the efficiency and effectiveness of the pharmaceutical industry through their innovative solutions. By utilizing computer modeling and simulation software, the company assists in predicting and optimizing drug properties, interactions, and outcomes. This enables scientists and researchers to make informed decisions throughout the drug development process, leading to improved efficacy, safety, and reduced costs. Simulations Plus Inc's comprehensive solutions cater to the needs of pharmaceutical companies, regulatory agencies, and academia worldwide.
Simulations Plus Inc is a leading provider of simulation and modeling software for the pharmaceutical and biotechnology industries. Established in 1996, the company has amassed extensive expertise in the field. Simulations Plus Inc has developed a strong reputation for its cutting-edge technology and innovative solutions, helping pharmaceutical companies optimize drug discovery and development processes. With a focus on increasing efficiency and reducing costs, Simulations Plus Inc has become a trusted partner for numerous organizations worldwide. The company's commitment to excellence has earned them recognition and a loyal customer base. Simulations Plus Inc continues to drive advancements in the industry, delivering impactful software solutions that streamline drug development.
Simulations Plus Inc has achieved significant milestones throughout its history. Some notable accomplishments include the development and release of their industry-leading software solutions, such as GastroPlus™ and DDDPlus™, which have gained widespread recognition and adoption in the pharmaceutical industry. The company has also formed strategic partnerships and collaborations with top pharmaceutical companies, further establishing its presence and credibility in the market. Additionally, Simulations Plus Inc has a strong track record of achieving consistent revenue growth and delivering value to its shareholders. These achievements reflect the company's commitment to innovation, excellence, and meeting the evolving needs of the life sciences industry.
Simulations Plus Inc is primarily present in the United States.
Simulations Plus Inc represents values of innovation, scientific excellence, and customer satisfaction. With a corporate philosophy focused on advancing pharmaceutical research and enhancing drug development, Simulations Plus Inc strives to provide cutting-edge software and consulting services. By combining advanced technologies and domain knowledge, the company facilitates cost-effective and efficient drug discovery and development processes. Simulations Plus Inc is committed to delivering high-quality solutions, fostering collaborative relationships, and continuously improving its products and services.
Analitikai šiuo metu nustato vidutinę Simulations Plus akcijos tikslinę kainą 18,50 USD (mediana: 18,50 USD), t. y. +0,0 % palyginti su paskutine kaina. Konsensusas pagrįstas 12 analitikų reitingais.
12 analitikai šiuo metu vertina Simulations Plus akciją: 0 rekomenduoja pirkti, 7 laikyti ir 5 parduoti. 2026 m. analitikai tikisi, kad Simulations Plus gaus 81,80 mln. USD pajamų ir 0,82 USD pelno akcijai.
Pagal dabartinį kursą Simulations Plus akcija kainuoja 16,50 EUR (18,50 USD).
Simulations Plus akcija (SLP) kotiruojama 1 biržose, įskaitant: NASDAQ (SLP).
Simulations Plus Inc. is a leading company in the field of simulation technology and software development. It provides solutions for researchers and experts in various industries, including biotechnology, pharmaceuticals, agriculture, food technology, and more. The company offers a range of products and tools for data analysis and innovative strategy development to bring new products and applications to the market. Some of its notable products include PK-SIM, MoBi, ADMET Predictor, GastroPlus, DILIsym, and MedChem Studio. Simulations Plus also offers solutions for the agricultural sector, such as Cartagenia, Crop Laptop, and Dose Response Toxicology. The company provides training and support to its customers, aiming to optimize their business processes. Its business model focuses on processing and analyzing large data sets to provide relevant insights and support decision-making processes. Simulations Plus aims to expand into new markets and develop products based on the latest technological advancements.
tikėtina pelnas Simulations Plus yra 81,80 mln. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas Simulations Plus yra 16,48 mln. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Simulations Plus šiuo metu yra 22,69. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Simulations Plus akcijos vertę.
Kainų ir pardavimų santykis (KUV) Simulations Plus šiuo metu yra 4,57. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Simulations Plus akcijos įvertinimo metrika.
Eulerpool kokybės balas Simulations Plus yra 3/10.
Simulations Plus ISIN yra US8292141053. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Simulations Plus WKN yra 924294. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Simulations Plus prekybos žymė yra SLP. Ši biržos žymė naudojama Simulations Plus akcijoms prekiauti biržoje.
Simulations Plus akcija
Simulations Plus Pagrindiniai konkurentai
Simulations Plus Biržos simbolis
Simulations Plus FIGI
Visos Simulations Plus pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Simulations Plus akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Simulations Plus. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: